Sanofi Finalizes Zentiva Sale With Focus Back On Turnaround
A share purchase agreement for the sale of Zentiva has been signed with private equity group Advent, so Sanofi can concentrate on making the most of its new acquisitions.
You may also be interested in...
Sanofi sells Indian facility to Zentiva, a key customer for products made at the site, and hopes to make up for the earnings gap through a renewed push for its “core activities and brands.”
The two firms hope improvement in the six-minute walk test might be accepted by the US FDA as registrational endpoint for reldesemtiv in spinal muscular atrophy. Blackstone acquires Clarus, while Merck licenses TriNKETs from Dragonfly.
Swedish rare diseases specialist Sobi has reported strong financials and the acquisition of a rare disease candidate on the verge of US approval. Could partner Sanofi pop the question soon?